10x Genomics (NASDAQ:TXG) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.30) by 33.33 percent. This is a 66.67 percent decrease over losses of $(0.24) per share from the same period last year. The company reported quarterly sales of $165.02 million which beat the analyst consensus estimate of $159.39 million by 3.53 percent. This is a 10.30 percent decrease over sales of $183.98 million the same period last year.